The Effect of Lifestyle Changes on Disease Severity and Quality of Life in Patients with Plaque Psoriasis: A Narrative Review

Acht, Maartje R van; Reek, J.M.P.A. van den; Jong, E.M.G.J. de; Seyger, M.M.B.

doi:10.2147/ptt.s294189

Cited by 6 publications

(8 citation statements)

References 69 publications

(193 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, studies investigating the relationship between sleep quality and disease activity in psoriasis and psoriatic arthritis give contradictory results ( 276 , 291 – 298 ). So far, studies on lifestyle interventions that affect sleep and investigate respective effects on disease activity are lacking ( 299 ). Impairment of sleep in patients with psoriasis, psoriatic arthritis and axial SpA increases the risk for psychiatric diseases, which themselves might impair sleep, resulting in a vicious circle ( 300 – 302 ).…”

Section: Epidemiological and Experimental Evidence That Shift Work Co...mentioning

confidence: 99%

Potential effects of shift work on skin autoimmune diseases

2023

View full text Add to dashboard Cite

Shift work is associated with systemic chronic inflammation, impaired host and tumor defense and dysregulated immune responses to harmless antigens such as allergens or auto-antigens. Thus, shift workers are at higher risk to develop a systemic autoimmune disease and circadian disruption with sleep impairment seem to be the key underlying mechanisms. Presumably, disturbances of the sleep-wake cycle also drive skin-specific autoimmune diseases, but epidemiological and experimental evidence so far is scarce. This review summarizes the effects of shift work, circadian misalignment, poor sleep, and the effect of potential hormonal mediators such as stress mediators or melatonin on skin barrier functions and on innate and adaptive skin immunity. Human studies as well as animal models were considered. We will also address advantages and potential pitfalls in animal models of shift work, and possible confounders that could drive skin autoimmune diseases in shift workers such as adverse lifestyle habits and psychosocial influences. Finally, we will outline feasible countermeasures that may reduce the risk of systemic and skin autoimmunity in shift workers, as well as treatment options and highlight outstanding questions that should be addressed in future studies.

show abstract

Section: Epidemiological and Experimental Evidence That Shift Work Co...mentioning

confidence: 99%

Potential effects of shift work on skin autoimmune diseases

2023

View full text Add to dashboard Cite

show abstract

“…The most common clinical form is psoriasis vulgaris, accounting for 90% of cases [ 6 ]. It is characterized by the presence of papular lesions on an erythematous base that is covered with silvery-white scales and localized to the scalp (most common), symmetrically on the upright parts of the upper and lower extremities, as well as in the lumbosacral region [ 6 , 7 ]. In contrast, palmoplantar psoriasis mainly involves the palms and soles, is characterized by significant treatment resistance, and significantly reduces the patient’s quality of life (QoL) [ 6 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

Effects of Alcohol Intake, Smoking, and Diet Evaluated Using the Alcohol Use Disorder Identification Test Questionnaire on the Severity of Plaque Psoriasis in 44 Patients Using the Body Surface Area and Psoriasis Area and Severity Index Scales, and Quality of Life Using the Dermatology Life Quality Index Questionnaire

Michalski¹,

Palazzo-Michalska²,

Michalska-Bańkowska³

et al. 2023

Med Sci Monit

View full text Add to dashboard Cite

Background This study aimed to evaluate the effects of alcohol intake, assessed using the Alcohol Use Disorder Identification Test (AUDIT) questionnaire, on the severity of plaque psoriasis using the Body Surface Area (BSA) and Psoriasis Area and Severity Index (PASI) scales, and quality of life using the Dermatology Life Quality Index (DLQI) questionnaire. Material/Methods The diagnosis of psoriasis was made based on the clinical picture. We enrolled 24 patients with psoriasis vulgaris, and the AUDIT test conducted at the time of follow-up indicated a possible risky/harmful pattern of alcohol consumption or alcohol dependence syndrome among the patients (>8 points). The comparison group consisted of 20 psoriatic patients and AUDIT <8 points. The BSA and PASI scales were used to determine the severity of psoriasis, and the DLQI questionnaire assessed patients’ quality of life and how they felt during the week preceding the survey. Results As the amount and frequency of alcohol consumed increased, the exacerbation of lesions measured according to the PASI and BSA scales was significantly higher ( P <0.05), and the quality of life decreased ( P <0.05). We noted that inadequate and excessive dietary intake of total protein, total fat, and assimilable carbohydrates were associated with statistically significantly higher values of BSA and PASI scores and, thus, more severe psoriatic lesions ( P <0.05). Conclusions An unbalanced diet, alcohol abuse, and smoking negatively affect the course of psoriasis vulgaris, hence the importance of patient education.

show abstract

“…1 This disease affects approximately 100 million people worldwide, affecting patients’ quality of life and increases the risk of early mortality. 2,3 Psoriasis may be associated with multiple comorbidities, such as psoriatic arthritis, obesity, type 2 diabetes mellitus and cardiovascular disease with multiple poor lifestyle factors such as smoking, lack of physical activity and stress. 2,3 Currently, many biologic options are available and approved for the treatment of plaque psoriasis including tumor necrosis factor alpha (TNF-α) inhibitors, interleukin (IL)12/23 inhibitors, IL-17 inhibitors, and IL-23p19 inhibitors.…”

Section: Introductionmentioning

confidence: 99%

“…2,3 Psoriasis may be associated with multiple comorbidities, such as psoriatic arthritis, obesity, type 2 diabetes mellitus and cardiovascular disease with multiple poor lifestyle factors such as smoking, lack of physical activity and stress. 2,3 Currently, many biologic options are available and approved for the treatment of plaque psoriasis including tumor necrosis factor alpha (TNF-α) inhibitors, interleukin (IL)12/23 inhibitors, IL-17 inhibitors, and IL-23p19 inhibitors. 4 Guselkumab, a human IgG1 monoclonal antibody approved for treatment of moderate-to-severe psoriasis in 2017 and psoriatic arthritis in 2020, selectively targets the p19 subunit of IL-23, leading to the disruption of the type 17 helper-T-cell/IL-17 pathway.…”

Section: Introductionmentioning

confidence: 99%

The Effectiveness of Risankizumab Following Guselkumab Failure in Moderate-to-Severe Psoriasis Patients: A Retrospective Study

Hamm,

Ramsoondar,

McGillis

et al. 2023

J Cutan Med Surg

View full text Add to dashboard Cite

Background Psoriasis is a chronic inflammatory skin disease with a strong genetic predisposition and autoimmune component that is often treated with immunomodulators such as biologic therapy. Guselkumab is a biologic treatment option that selectively targets the p19 subunit of interleukin (IL)−23; risankizumab is a more recently developed monoclonal antibody of the same class that targets IL-23p19. There is limited research around effective treatment response with intra class switching within IL-23-targeted therapies for the treatment of moderate-to-severe plaque psoriasis. Objectives The purpose is to assess patient response to risankizumab after guselkumab failure for the treatment of plaque psoriasis. Methods A retrospective chart review was conducted for 13 patients meeting inclusion criteria. Physical examination findings were converted to a 5-point static physicians’ global assessment (sPGA) score. Baseline, 4-month, and 12-month sPGA scores were assigned from visits immediately prior to and during their course of risankizumab treatment. sPGA scores were analyzed to compare changes between baseline and 4 months and 12 months of therapy. Results Patients treated with risankizumab had lower sPGA scores after both 4 and 12 months compared to their baseline sPGA score. 46% of patients met the primary outcome of an sPGA score of 0 or 1 at 4 months of risankizumab, increasing to 90% of patients at 12 months. Conclusions Our findings reflect an improvement in sPGA scores when patients are treated with risankizumab following guselkumab failure. This highlights the benefit of in-class switch to risankizumab when patients with moderate-to-severe plaque psoriasis have failed multiple treatments including guselkumab.

show abstract

The Effect of Lifestyle Changes on Disease Severity and Quality of Life in Patients with Plaque Psoriasis: A Narrative Review

Cited by 6 publications

References 69 publications

Potential effects of shift work on skin autoimmune diseases

Potential effects of shift work on skin autoimmune diseases

The Effectiveness of Risankizumab Following Guselkumab Failure in Moderate-to-Severe Psoriasis Patients: A Retrospective Study

Contact Info

Product

Resources

About